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College of Pharmacy, Chicago, IllinoisABSTRACT Elucidating the principles governing anesthetic-protein interactions requires structural determinations at high
resolutions not yet achieved with ion channels. Protein kinase C (PKC) activity is modulated by general anesthetics. We solved
the structure of the phorbol-binding domain (C1B) of PKCd complexed with an ether (methoxymethylcycloprane) and with an
alcohol (cyclopropylmethanol) at 1.36-A˚ resolution. The cyclopropane rings of both agents displace a single water molecule
in a surface pocket adjacent to the phorbol-binding site, making van der Waals contacts with the backbone and/or side chains
of residues Asn-237 to Ser-240. Surprisingly, two water molecules anchored in a hydrogen-bonded chain between Thr-242 and
Lys-260 impart elasticity to one side of the binding pocket. The cyclopropane ring takes part in p-acceptor hydrogen bonds with
the amide of Met-239. There is a crucial hydrogen bond between the oxygen atoms of the anesthetics and the hydroxyl of
Tyr-236. A Tyr-236-Phe mutation results in loss of binding. Thus, both van der Waals interactions and hydrogen-bonding are
essential for binding to occur. Ethanol failed to bind because it is too short to benefit from both interactions. Cyclopropylmethanol
inhibited phorbol-ester-induced PKCd activity, but failed to do so in PKCd containing the Tyr-236-Phe mutation.INTRODUCTIONGaining a detailed understanding of the intermolecular
interactions governing anesthetic-protein interactions is a
critical step in elucidating the molecular mechanisms under-
lying general anesthesia and in developing more selective
anesthetic agents (1–5). However, little progress can be
made until such intermolecular interactions are character-
ized at high resolution. The physiological sites of anesthetic
action remain difficult to define, and some potential targets,
such as the transmembrane domains of the mammalian
ligand-gated ion channel superfamily, are poorly character-
ized. Furthermore, the structures of prokaryotic channels
have been solved at low resolution (6–8) relative to that
necessary to reveal atomic-level principles governing anes-
thetic binding (9–11). Consequently, crystallizable soluble
proteins have been used as surrogate targets to obtain struc-
tural information on protein-anesthetic interactions (12–18).
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0006-3495/12/12/2331/10 $2.00duction, they provide principles of protein-anesthetic inter-
actions that may apply at any site.
Protein kinase C (PKC), a key signal transduction protein,
has been proposed as the target of anesthetics such as
alcohols, halothane, and enflurane (19,20) (for a review,
see Rebecchi and Pentyala (21)). The PKC family of
serine-threonine kinases plays a central role in signal trans-
duction mediated by lipid second messengers such as sn-1,2
diacylglycerols, regulating divergent cellular functions by
phosphorylation of target proteins such as ion channels
(22,23). Members of the PKC family that respond to DGs
can be separated into two major categories; the conventional
(a, bI, bII, g) and the novel (d, ε, q, h) PKCs, each with four
domains, termed C1–C4, which play distinct roles in kinase
function. C1 and C2 are regulatory domains, C3 is the ATP-
binding domain, and C4 is the catalytic domain. The C1
domain is a tandem repeat of highly conserved cysteine-
rich zinc finger subdomains C1A and C1B. These domains
differ in their binding affinities for phorbol esters and sn-1,2
diacylglycerols (24–27).
In intact PKCa, volatile anesthetics and long- and short-
chain alcohols modulate PKC activation in vitro and alter
the binding affinities of activators. The isolated catalytic
domain, C4, is unaffected by anesthetics, indicating that
the primary anesthetic interaction occurs within the regula-
tory domains, most likely C1, because these agents interact
allosterically with phorbol binding (19,26,28,29). To test
this hypothesis, we chose PKCd. Although it is the least
sensitive to anesthetics (30), its phorbol-binding domain
(C1B) is the only one for which a crystal structure ishttp://dx.doi.org/10.1016/j.bpj.2012.10.034
2332 Shanmugasundararaj et al.available (31). We previously used azialcohols to photolabel
Tyr-236 on this domain of PKCd (32). Encouraged by
this finding, we have now solved high-resolution crystal
structures of unliganded PKCd C1B as well as complexes
with methoxymethylcycloprane (CPE) and cyclopropylme-
thanol (CPM). Both compounds bind in the same surface
pocket, forming a single hydrogen bond to Tyr-236.
Eliminating the hydrogen bond by mutation of Tyr-236 to
phenylalanine resulted in no detectable alcohol binding.
Furthermore, we show that this binding site is important
in anesthetic-induced inhibition of PKCd activity.MATERIALS AND METHODS
Reagents
Glutathione Sepharose 4B was obtained from Amersham Biosciences
(Piscataway, NJ). Protein concentration was determined with a BCA protein
assay reagent kit (Pierce, Rockford, IL). COS-7 cells were purchased from
the American Type Culture Collection. Dulbecco’s modified Eagle’s
medium, L-glutamine, and penicillin-streptomycin were purchased from
Invitrogen (Carlsbad, CA). Fetal bovine serum, Anti-Flag affinity gel,
Histone-IIIS, Phorbol 12-myristate 13-acetate (PMA), CPM, and all other
reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise noted. sn-1,2 Dioleoylglycerol (DG) and L-a-phosphatidylserine
(PS) were purchased fromAvanti Polar Lipids (Alabaster, AL). [32g-P]ATP
was purchased from PerkinElmer Life Sciences (Waltham, MA).Expression, purification, and characterization
of PKCd C1B
PKCd C1B and its mutants were expressed in Escherichia coli as gluta-
thione S-transferase fusion products, purified by glutathione-Sepharose
affinity chromatography, and characterized by circular dichroism spectra
as previously described (32). Before crystallization, the protein was further
purified by fast-performance liquid chromatography (BiologicWorkstation,
BioRad, Hercules, CA) using a Superdex 75 column (GE Healthcare,
Uppsala, Sweden), a mobile phase of 50 mM Tris, 100 mM NaCl, pH
7.0, and a flow rate of 0.5 ml/min (32).Site-directed mutagenesis of PKCd C1B
Site-directed mutagenesis of the glutathione-S-transferase-PKCd C1B was
performed using the QuikChange kit (Stratagene, La Jolla, CA). One round
of polymerase chain reaction (PCR) amplification was carried out using two
suitably designed complementary primers, and the variant was amplified
by PCR in the pGEX plasmid containing the C1B domain sequence (kindly
provided by P. M. Blumberg of the National Institutes of Health National
Cancer Institute). DNA sequences were confirmed at the Massachusetts
General Hospital DNA sequencing facility.Crystallization, protein-alcohol complex
formation, and data collection
Crystallizationwas carried out at 293Kusing the hanging-drop vapor-diffu-
sion method. Initial screening was with crystallization screens (Hampton
Research, Aliso Viejo, CA). The hanging-drop solution contained equal
volumes (2 ml) of a solution containing 25 mg/ml protein and the reservoir
solution. The reservoir solution consisted of 20% polyethylene glycol
(PEG) 3350 in 0.2 M ammonium sulfate and 25 mM HEPES, pH 7.2. TheBiophysical Journal 103(11) 2331–2340crystals exhibited plate morphology and reached their full dimensions of
0.05  0.2  0.5 mm within a week. For cocrystallization, anesthetic was
included in the reservoir solution. For soaking, preformed crystals were
incubated in reservoir solution supplemented with anesthetic.
During cocrystallization, loss of anesthetic was monitored by headspace
gas chromatography performed on an HP 5890 (Agilent Technologies, Palo
Alto, CA) using a DB-17HT column (30 m  0.321 mm, 0.15 mm from
J&W Scientific, Philadelphia, PA). When 0.5 M CPM in 0.2 M ammonium
sulfate and 20% PEG 3350 was present during cocrystallization, 40% of
CPM was lost over a 4-week period, which is twice as long as the usual
cocrystallization condition time.
Crystals were flash-frozen in liquid nitrogen in 40% PEG 3350 in the
buffer 5 anesthetic. Synchrotron data were collected at beam lines X6A
(National Synchrotron Light Source, Brookhaven National Laboratory,
Upton, NY) and 8BM (Advanced Photon Source, Argonne National Labo-
ratory, Argonne, IL). Images were integrated and scaled using DENZO and
SCALEPACK as implemented in HKL-2000 (33). Crystals belonged to the
space group P21 and contained two molecules in the asymmetric unit. Data
collection and refinement statistics are given in Table 1.Structure determination and refinement
ThePhenix suite (34)was used for the final structure solution and refinement.
The 1.95-A˚ structure of PKCd (Protein Data Bank code, 1PTQ) was the
search model in molecular-replacement calculations. The AutoMR program
provided the correct solution with two molecules in the asymmetric unit.
After a few cycles of refinement and convergence, the model was manually
checked using COOT (35). The refinement and model building were then
repeated until Rwork and Rfree converged to constant values. This model
was then anisotropically refined until such convergence occurred (Table 1).
The same procedure was followed for the complexes with anesthetics.
After the convergence of the refinement of the protein model, if extra
electron density was found near Tyr-236, appropriate ligands were fit into
that density and refined. Adjustments of models were made at the end of
each refinement cycle guided by 2Fo – Fc and Fo – Fc electron density maps.
Using a standard protocol implemented in CNS, we refined the structures
and calculated simulated annealing omit maps for each structure (36) to
eliminate model bias for molecules occupying the binding site. A box
including the ligand was defined and enlarged by 2 A˚ on each side. A refine-
ment protocol, including simulated annealing from 1000 to 50 K and energy
minimization, was then carried out without using any of the atoms inside
the box. Electron density for the entire structure was then calculated using
the phases derived from this procedure, resulting in maps that are indepen-
dent of the contribution from the molecule within the box.Anesthetic potency
General anesthetic potency was assessed with institutional approval in pre-
limb-bud Xenopus tadpoles 1.5–2 cm in length (Xenopus 1, Dexter, MI), as
previously described (37,38).Cell culture and plasmids for PKCd
COS-7 cells were grown in Dulbecco’s modified Eagle’s medium, supple-
mented with 10% fetal bovine serum, 2 mM glutamine, 100 mg/mL strepto-
mycin, and 100 units/mL penicillin. The cells were maintained at 37C, in
a humidified atmosphere of 90% air and 10% CO2. Flag-epitope-tagged
PKCd was generated by PCR using pRSV-rat PKCd (provided by Peter. J.
Parker, Imperial Cancer Research Fund, London, UK) as the template with
50 primer (50-CGCGGATCCATGGACTATAAGGACGATGATGACAAAG
CACCGTTCCTGCGCATCTCCTTC-30) and 30 primer (50-CCGGAATTC
CTATTC CAGGAATTGCTCATATTTGG-30). The PCR product was
digested with BamHI and EcoRI, and ligated into pcDNA3 (Invitrogen) to
add the epitope tag. The PKCd Tyr-236-Phe mutant (PKCd Y236F) was
TABLE 1 Data collection and refinement statistics
Wild-type C1B CPM CPE C1B Tyr-236-Phe
Data collection
Space group P21 P21 P21 P21
Cell dimensions
a, b, c (A˚) 43.598, 32.475, 49.965 43.715, 32.597, 49.719 43.530, 32.459, 49.584 43.876, 32.522, 49.816
b () 94.10 94.21 94.55 94.02
Resolution (A˚) 30.0–1.30 (1.35–1.30) 30.0–1.36 (1.38–1.36) 30.0–1.36 (1.38–1.36) 30.0–1.3 (1.35–1.30)
*Rmerge 8.2 (36.3) 5.3 (34.9) 6.8 (37.0) 11.2 (46.8)
I/sI 19.7 (2.6) 19.8 (1.9) 20.9 (2.0) 16.1 (1.2)
Completeness (%) 99.5 (99.0) 97.0 (78.9) 98.8 (93.8) 95.7 (79.3)
Redundancy 4.3 (4.0) 4.3 (3.2) 4.5 (3.6) 4.0 (3.2)
Refinement
Ramachandran plot
Most favored (%) 92.1 92.1 93.0 92.1
Allowed (%) 7.9 7.9 7.0 7.9
Total number of reflections 32,058 28,244 27,793 30,558
yRwork/Rfree 14.2/15.8 14.7/17.0 15.3/18.2 18.8/22.8
Est. coordinate error (A˚) 0.13 0.14 0.16 0.17
RMS deviation of
Bond lengths (A˚) 0.007 0.006 0.006 0.007
Bond angles () 1.21 1.09 1.09 1.13
Values in parentheses refer to the last shell. Rfree was computed for 5% randomly selected reflections (61). Est., estimated.
*Rmerge ¼ ShklSijIi (hkl)  <I(hkl)>j/ShklSiIi(hkl), where the summation is over all symmetry-equivalent reflections, excluding reflections observed
only once.
yRwork ¼ ShkljFo(hkl) – kFc(hkl)j/ShkljFo(hkl)j, where Fo and Fc are the observed and calculated structure factors, respectively.
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with 50 primer (50-CCTCACCGATTCAAGGTCTTCAACTACATGAGCC
CCAC-30) and 30 primer (50-GTGGGGCTCATGTAGTTGAAGACCTTG
AATCGGTGAGG-30).Kinase expression and purification
FLAG-PKCd (wild-type or Y236F) plasmids (10 mg) were transfected into
COS-7 cells plated in 10-cm plates using Superfect (Qiagen, Hilden,
Germany). After 72 h, the cells were washed first in phosphate-buffered
saline and then with lysis buffer containing 50 mM Tris-HCl, pH 7.4,
150 mMNaCl, 1 mM EDTA, 1% Triton X-100, phosphatase inhibitor cock-
tail 1 (Roche Applied Science, Penzberg, Germany), and complete protease
inhibitor cocktail (Roche Applied Science). After 20 min on a rocker at
4C, cells were collected and centrifuged (12,000  g, 10 min). Superna-
tants were added to anti-FLAG M2-agarose gel (Sigma-Aldrich) and incu-
bated at 4C for 3 h. The beads were transferred to a column and washed
sequentially with 15 ml of lysis buffer, 15 ml of buffer B (150 mM NaCl
and 50 mM Tris-HCl, pH 7.4) and 5 ml of PKC storage buffer (20 mM
HEPES, pH 7.4, 250 mM NaCl, 2 mM EGTA, 2 mM EDTA, 5 mM DTT,
50% glycerol, and 0.05% Triton X-100). To elute FLAG-tagged proteins,
the beads were incubated with PKC storage buffer containing 0.15 mg/ml
3X FLAG peptide (Sigma-Aldrich) for 30 min at 4C and then centrifuged
for 10 s at 10,000  g. Concentrations of wild-type and Y236F PKCd were
determined by comparison with purchased recombinant PKCd (Invitrogen)
using Sypro Ruby (Molecular Probes, Eugene, OR). The kinases were ali-
quoted and stored in PKC storage buffer at –80C.In vitro PKCd kinase assay
PKCd (10 nM) was added to kinase buffer containing 20 mM HEPES, pH
7.4, 10 mM MgCl2, 0.1 mM EGTA, 0.23% TritonX-100, and 1 mM dithio-
threitol in 30 mL with 0.28 mg/mL Histone-IIIS, with or without 300 mM
CPM, as indicated. The reaction was started by adding either 150 nM
PMA and 8% PS, or 4% DG and 8% PS, prepared in 3% TritonX-100micelles, followed by 20 mM ATP and 0.5 mCi [32g–P]ATP (39).
The PMA stock was in dimethylsulfoxide, whose final concentration in
the reaction mixture was 3%. Controls showed that the inhibitory action
of CPM was the same at 0.015% and 3% dimethylsulfoxide. After
30 min at 37C, the reaction was terminated by adding sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer
and heating (95C for 5 min). Samples (12 mL) were separated by SDS-
PAGE (4–12% Bis-Tris gradient gels; Invitrogen). Radioactivity incorpo-
rated into histone III-S was quantified by phosphorimaging (Typhoon
9410, GE Healthcare). Specific PKCd activity was calculated as the
difference between total counts per minute measured with (PMA þ PS)
or (DG þ PS) minus nonspecific activity measured in the absence of
activators. Percentage inhibition by CPM was calculated as (1  (specific
PKCd activity with inhibitor/specific activity without inhibitor))  100.RESULTS
Characterization of proteins and agents
Purified PKCdC1B and its mutant Tyr-236-Phe both showed
a single band ~7 kDa on 18% SDS-PAGE (data not shown)
(32) and migrated as single symmetrical peaks with the ex-
pected Stokes radius by fast-performance liquid chromatog-
raphy on a gel filtration column. The mutant’s circular
dichroism spectra between 195 and 240 nm were similar to
that of the wild-type C1B. Spectra for both proteins had
secondary structures very similar to those previously re-
ported (50% b-sheet, 7% a-helix, remainder random) (32).
CPE was synthesized by a routine Williamson ether
synthesis with excess CPM as solvent. Sodium (460 mg,
20 mmol) was added in small portions to CPM (2.88 g,
40 mmol; two-fold excess) and stirred at room temperature
until evolution of hydrogen gas ceased (a thick slurry ofBiophysical Journal 103(11) 2331–2340
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(2.84 g, 20 mmol) was added, and the mixture was stirred
for 2 h (white sodium iodide solid was observed). CPM
and CPE were distilled off, and the ether was separated by
five to seven aqueous extractions of 5 mL each to afford
pure ether (1.52 g, 88%). The analytical data were analo-
gous to those described earlier (40).
CPE-induced loss of righting reflexes was determined in
four groups of six tadpoles exposed to 1–15 mM CPE.
Quantal analysis yielded an EC50 of 55 1.2 mM and a slope
of 3 5 1.5. The published EC50 value for CPM is 54 5
3.2 mM (41).FIGURE 1 The overall structure of the PKCd C1B subdomain com-
plexed with CPM. (A) CPM (cyan) binds to the protein in a pocket created
by Tyr-236, Asn-237, Tyr-238, Met-239, and Ser-240, and its hydroxyl
group is hydrogen-bonded (dashed line) to Tyr-236 (2.8 A˚). The site
includes both Tyr-236 (gold), photolabeled by azialcohols, and part of
the phorbol-binding site (Met-239, Ser-240) discovered by Hurley’s
group (31). Dashed lines are the coordination bonds to zinc (purple).
(B) Surface representation in the same orientation as in A. Tyr-236,
Tyr-238, Met-239, and Ser-240 are visible through the translucent surface.
Nitrogen and oxygen atoms are blue and red, respectively. Molecular
graphics images were produced using the UCSF Chimera package (59)
(see Acknowledgments).Crystal structures of the wild-type PKCd C1B
domain
Our crystals of the PKCd C1B domain belonged to space
group P21 and contain two molecules of the protein in the
asymmetric unit (see Materials and Methods). Both mole-
cules in the asymmetric unit of our crystals are nearly iden-
tical in structure, with a root-mean-square deviation (rmsd)
of 0.25 A˚ for Ca. All 65 residues of each chain could be
built into the electron density maps, including the 50 resi-
dues of the C1B domain and the 15 residues of the construct
that were not previously reported (Table 1).
Our wild-type structure, which superimposed well on that
previously published (rmsd of 0.27 A˚ for the Ca atoms of
residues His-231 to Cys-280) (31), had all residues within
the allowed region of the Ramachandran plot, well-defined
side chains, and stereochemical parameters well within the
statistical error (Table 1). Our structure has an especially
low coordinate error of 0.13 A˚, calculated using the Luzzati
plot (42) (Table 1), allowing us to discuss interactions with
high accuracy. The B-factors (Fig. S1 in the Supporting
Material) are lowest (7–11 A˚2) at the Cys and His residues
coordinating the two zinc ions and tend to be higher
(~17–26 A˚2) in the loop regions and around the residues
previously shown to be in contact with phorbol esters
(Fig. 1 and Fig. S2) (31), an observation consistent with
a recent NMR study (43).
In the phorbol-binding site, 11 water molecules form an
extensive hydrogen-bond network (Fig. S2 A). Water-71
and Water-84 form a four-sided hydrogen-bonded ring
linking the carboxyl oxygens of Tyr-238 and Leu-254.
The remaining waters form a hydrogen-bonded network
each with two to four hydrogen bonds in the vicinity of
Pro-241 and Gly-253.
In the vicinity of Tyr-236, there are three water molecules
that play important roles in ligand binding. Water-1 is
hydrogen-bonded to the amide nitrogen of Met-239
(3.1 A˚). It is tightly held on the axis of that bond but
undergoes significantly higher motion parallel to the back-
bone. Water-2 and Water-3 form a hydrogen-bonded chain
between Thr-242 and Lys-260 (2.7–2.9 A˚). The anisotropic
B-factors indicate that motion along one axis perpendicularBiophysical Journal 103(11) 2331–2340to the hydrogen bonds is greater than that in line with the
bonds, as shown by the thermal ellipsoids in Fig. 2 A.
An interesting observation was that in each molecule, the
construct’s C- and N-terminal residues form a two-stranded
antiparallel b-sheet (Fig. S3). Two such sheets from mole-
cules in adjacent unit cells interact to form a four-stranded
antiparallel b-sheet held together by four (2.8–2.9 A˚) back-
bone intermolecular hydrogen bonds, with each pair of
Ala-226 and Val-228 residues contributing two of these
bonds. This structure propagates to form an array of ex-
tended planar sheets of C1B domains sandwiched between
similar sheets of solvent.Crystal structures of PKCd’s C1B domain
in the presence of anesthetics
The structure of C1B cocrystallized in the presence of
500 mM CPM was solved to 1.36 A˚. A similar structure
was obtained by soaking a preformed crystal with
500 mM CPM (data not shown). The unit cell and the struc-
ture of C1B were unchanged by CPM; the rmsd for the Ca
atoms compared to the unliganded structure was 0.06 A˚
(His-231 to Cys-280). CPM tended to slightly lower
isotropic B-factors except in the loop regions (Fig. S1).
It is important in small ligand studies to establish that any
excess density originates from the added ligand and is not an
artifact of the crystallization conditions, such as changes
in hydration or the presence of PEG (44). We chose CPM
FIGURE 2 Details of the structure of the anes-
thetic binding site and the phorbol-binding cleft
of the PKCd C1B subdomain. Carbon atoms are
colored gray, oxygen atoms red, nitrogen atoms
blue, and sulfur atoms yellow. Thermal ellipsoids
at 50% probability represent the water molecules.
Waters in the phorbol cleft are omitted for clarity
(see Fig. S2 for details). Ligand carbons are
cyan. The 2Fo electron density map of the protein
(green mesh) is drawn at 1s cut-off. The equivalent
maps around the ligands and water (magenta mesh)
are at 1s, except for CPE where the map is drawn
at 0.9s cut-off. (A) Wild-type C1B containing a
water molecule (Water-1) at the anesthetic site.
Water-2 and Water-3 form a hydrogen-bond net-
work connecting Thr-242 and Lys-260. (B) CPM
bound to C1B. CPM forms a hydrogen bond with
Tyr-236. Water-2 and Water-3 form one side of
the ligand-binding pocket. The hydroxyl of Ser-
240 now adopts two rotamers. (Inset) Thermal
ellipsoid representation of CPM. (C) CPM bound
to C1B. The hydroxyl of Ser-240 again adopts
two rotamers. (Inset) Thermal ellipsoid represen-
tation of CPE. (D) Structure of the C1B mutant
Tyr-236-Phe. Awater molecule occupies the anes-
thetic binding site in a way very similar to that ob-
served for the wild-type. Neither CPM nor CPE
were detected in this mutant (see text). Figures
were prepared using Chimera (59).
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would aid in validating the assignment. After refinement
of the protein model, extra electron density was found
near Tyr-236 (Fig. 2 B and Fig. S5 A). This density consisted
of a triangular blob with one side close to the backbone of
residues Met-239 and Ser-240. From the apex opposite
this side of the triangle there was an extension of the elec-
tron density toward Lys-260. The triangular excess density
could be fitted with a cyclopropane ring. The remaining
positive density could not be satisfactorily fitted by adding
water molecules, but an excellent fit was obtained with
CPM leaving no residual density at 3.6s (Fig. 2 B). The
oxygen was well placed to form a hydrogen bond with
Tyr-236’s hydroxyl (2.8–3.0 A˚) (Fig. 3).
The structure with bound CPE was determined at a resolu-
tion of 1.36 A˚. The position of the cyclopropane ring was
similar to that of CPM, and the side chain exhibited a similar
degree of mobility. The ether oxygen was well positioned to
form a hydrogen bond to Tyr-236, whereas the terminal
methyl (C5) was ill-defined, suggesting rotation around
the C1—O bond (Figs. 2 C).
Once the models were complete, omit maps were calcu-
lated, confirming the presence of water or ligand in the
electron density (see Fig. S5).
Water-1, adjacent to Met-239 and displaced by CPM and
CPE, was not displaced when crystals were soaked in the
following agents: ethanol,%10 M; propanol, 3 M; butanol,
1 M; octanol, 4 mM; chloropropanol, 0.5 M; bromobutanol
20 mM; and chloroform 0.5 M.Crystal structure of PKCd’s C1B domain
with the mutation Tyr-236-Phe
Thismutant also crystallized in the native condition, yielding
similar platelike crystals. No significant deviation was
observed in the unit-cell parameters, and superposition on
the wild-type structure gave an rmsd of 0.16 A˚ for the Ca
carbons of all 128 residues of the two copies present in
the asymmetric unit, indicating that the overall structure
and crystal packing are very similar in both the wild-type
and mutant structures. The only change was the loss of the
solvent-exposed tyrosine hydroxyl group (Fig. 2 D). Minor
increases in the B-factors of the residues adjacent to
Phe-236 were also observed, but not in the aromatic ring
itself. The statistics are given in Table 1 and the omit map
is shown in Fig. S5 D.
The mutant Tyr-236-Phe C1B was cocrystallized with
0.3 and 0.5 M CPM, and structures were determined for
both. In addition, two different data sets were collected
for crystals soaked with 1 M CPM. These conditions are
similar to those successfully employed with wild-type
C1B, but although the resolutions were all comparable
to those of the unliganded mutant, in no case was excess
electron density found. We therefore conclude that the two
ligands do not bind to Tyr-236-Phe C1B.Pharmacology of protein kinase Cd activity
DG stimulated Histone-IIIS phosphorylation by three- to
fourfold and PMA stimulated it by approximately twofoldBiophysical Journal 103(11) 2331–2340
FIGURE 3 Interactions between CPM and the C1B domain of PKCd.
The carbons of the ligand are in cyan and are numbered for reference by
superimposed red numerals. The unliganded structure (magenta) is omitted
unless it is different from that of the ligand-bound structure (light blue).
Oxygen is red, nitrogen is blue, except that the waters in the unliganded
state are magenta. Distances are in A˚ngstroms. The ligand’s hydroxyl
forms a hydrogen bond to Tyr-236. Good van der Waals contact is made
between the ligand and several residues, as well as Water-2 and Water-3,
which are hydrogen-bonded between Thr-242 and Lys-260 (see text). The
ligand-bound structure shows two rotamers for Ser-240; one of these super-
poses with the single wild-type structure. The ligand replaces water-1,
whose thermal ellipsoid is shown) (see Discussion). The figure was
prepared using Chimera (59).
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the Tyr-236-Phe mutation. CPM inhibited basal activity by
~20%, independent of the presence of the mutation. After
correction for this effect on basal activity, CPM still in-
hibited DG-stimulated activity of wild-type rat PKCd in a
concentration-dependent manner, but at a concentration
R600 mM, inhibition was only partially reversible. There-
fore, all further experiments were carried out using 300 mM
CPM, which reversibly inhibited DG-stimulated PKCd
activity by 35–40%, independent of the Tyr-236-Phe muta-
tion (Table 2). CPM also inhibited PMA-stimulated wild-
type PKCd to a similar extent. In contrast, it was barelyTABLE 2 Inhibition of PKCd activity by CPM
PKCd
Percent inhibition of stimulated activity by 300 mM CPM
DG PMA
mean SE n mean SE n
Wild-type 39.4 5 7.2 3 27.5 5 3.4 7
Tyr-236-Phe 35.5 5 4.8 3 7.1* 5 1.3 7
Each data point in each experiment was calculated as the average of three to
five replicates. n is the number of independent experiments.
*p ¼ 0.0001 compared with wild-type PKCd activated with PMA (two-
tailed, unpaired t-test).
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(Table 2). The PMA-activity concentration-response curve,
determined over the range 10–1,000 nM, fit mass-action
kinetics (see Fig. 4). In the presence of 300 mM CPM, the
EC50 for PMA was unchanged (p ¼ 0.9) for wild-type
PKCd, but the maximal effect was reduced significantly
(p ¼ 0.02), consistent with noncompetitive inhibition. In
contrast, CPM did not alter the EC50 or the maximal effect
of PMA for PKCd Tyr-236-Phe.DISCUSSION
We have determined structures at 1.36-A˚ resolution of the
mouse PKCd C1B phorbol-binding domain complexed
with an alcohol, CPM, and its methyl ether, CPE. The anes-
thetics bind near the side chain of Tyr-236, a residue that has
been photolabeled in solution by 3-azioctanol and 3-azibu-
tanol (32), affirming the utility of photoaffinity labeling.
The anesthetic binding site is unusual. First, there is no
a-helix in contact with the anesthetic, whereas this motif
is often present at general anesthetic sites in ion channels,
soluble proteins, and model systems (9–11,16,45). Instead,
part of the pocket is formed by a loop between two b-sheets.
This loop motif is not uncommon, but it usually occurs
together with other motifs in anesthetic-binding pockets
such as those on albumin, cholesterol oxidase, luciferase,
and LUSH (45) (Fig. S4). Second, the site is a shallow
surface pocket in which the bound ligand remains partially
exposed to the solvent. The sites in LUSH and luciferase
are inaccessible to bulk solvent (45–47), although that of
halothane in human serum albumin is less buried (16).FIGURE 4 Comparison of the action of CPM on phorbol-stimulated
PKCd activity in wild-type and mutated (Tyr-236-Phe) PKCd. The points
from three separate experiments were fit to the mass-action equation.
Results of the analysis are given in the table below.
PKCd Agent EC50 5 SD Max activity5 SD
Wild-type — 1655 38 4755 35
Wild-type þ CPM 1865 37 3115 20
Tyr-236-Phe — 2155 58 4755 43
Tyr-236-Phe þ CPM 1625 40 4065 31
Anesthetic Site on Protein Kinase Cd’s C1B Domain 2337We have obtained the highest-resolution anesthetic-
bound structures reported to date for signal transduction
proteins with the exception of butanol bound to LUSH
(1.25 A˚, PDB 1OOH) (45). Anesthetics interact with resi-
dues from Tyr-236 to Ser-240, as well as with Thr-242
and Lys-260 (Figs. 1 and 2 and Fig. S5), on the loop between
the strands of a b-sheet. The backbone amide of Tyr-236 is
the only part of this sequence to take part in the preceding
b-sheet. The remaining residues in the loop arch over the
binding pocket, opening up on the other side to form the
phorbol-binding cleft (Fig. 1), in which the phorbol ester
interacts with residues Met-239, Pro-241, and Thr-242,
and also with Leu-250, Leu-251, Gly-253, and Leu-254
(Fig. S2) (31).Role of van der Waals interactions
Binding of anesthetics is stabilized by van der Waals inter-
actions with the backbone and side chains of C1B and with
water, as well as by hydrogen-bonding interactions with the
protein and the solvent. These interactions are considered
in order below. We have adopted the numbering convention
for the ligand carbons that is given in Fig. 3. C1 is the carbon
between the cyclopropane ring and the oxygen, C2 is the
adjacent ring carbon, and C3 and C4 follow counterclock-
wise. The methyl group in CPE is C5. Force fields in
proteins are complex. We have empirically judged the
strength of van der Waals interactions using Tsai’s tabula-
tion of radii (48) and assuming pure dispersion forces. These
assumptions place the distance of maximum interaction in
the range 3.3–4.1 A˚ and that of half-maximum interaction
in the range 3.8–4.9 A˚, This provides a conservative esti-
mate of interaction strength, because static dipolar contribu-
tions operate over a longer range.
A major source of van der Waals interactions is between
the cyclopropane ring and the backbone atoms running from
the carboxyl oxygen of Asn-237 (4.1 A˚) through to the
amide nitrogen of Ser-240 (3.8 A˚) (see Fig. 3). The position
of the cyclopropane ring in the ether and alcohol derivatives
is nearly identical; distances given are for CPM. The C4
to Met-239 backbone amide nitrogen interaction is parti-
cularly short-range (3.0 A˚), suggestive of a p-ring.NH
interaction (42,49). Side chains also provide significant
van der Waals interactions (Fig. 3). Strong interactions are
observed with Met-239 (Cg being 3.5 A˚ from the cyclopro-
pane ring’s C4) and Tyr-236 (Cε being 3.9 A˚ from C4).
Tyr-236 and Tyr-238 provide an aromatic character to the
bottom of the binding pocket that may interact favorably
with the partially aromatic cyclopropane rings of the
ligands. Weaker interactions (~4.5 A˚) are seen with the
side chains of Tyr-238, Ser-240, Thr-242, and Lys-260.
An unusual feature of this ligand-binding site is that two
water molecules (Water-2 and Water-3), which are anchored
in a hydrogen-bonding chain stretching from Thr-242 to
Lys-260, provide tight van der Waals interactions (%3 A˚)along one side of CPM and CPE (O, C1, C2, and C3 atoms).
These water molecules impart elasticity to the site, being
displaced 0.5–0.7 A˚ upon ligand binding without breaking
the hydrogen-bonding chain between Thr-242 and Lys-260
(Fig. 3).
The ligands showed very little B-factor anisotropy (Fig. 2,
B and C, insets), but their B-factors were higher than those
of the atoms contacting them. Indeed, the B-factors are
greater than those for the terminal atoms of the longer
amino acids, suggesting that the ligands exhibit consider-
able motion in the binding pocket, as might be expected
for such low-affinity agents.Role of hydrogen-bonding
Both ligands form a hydrogen bond with Tyr-236 (2.8–3.0 A˚
in length). The ether can only accept a hydrogen bond from
Tyr-236, ruling out a contribution from tyrosinate. These
hydrogen-bond lengths compare well to the values of 2.6–
3.3 A˚ reported for propofol bound to human serum albumin
(Fig. S4 C) and butanol bound to LUSH (50,51) (Fig. S4, A
and B). In the cytoplasmic domain of Kir2.1, 2-methyl-2,4-
pentanediol forms a hydrogen bond (2.6–3.0 A˚) with Tyr-
337 (52).
The cyclopropane ring is a common motif in drugs. It has
been hypothesized, based on spectroscopic evidence (53)
and on surveys of the structures of small molecules
(42,54), that cyclopropane rings take part in X-H donor-
to-p-acceptor hydrogen bonds. To test whether this occurs
in protein-ligand interactions, we compared the interaction
between CPM’s ring and the backbone amide protons of
Met-239 and Ser-240 and the oxygen of Water-2 to the
examples of the 22 small molecules given in the above
survey (42) (Fig. S6). The two >N–H interactions occupy
positions on the boundaries of that data set (Fig. S6, A and
C); the interaction of Met-239 is of unusually short range
for the angle of interaction, whereas that of Ser-240 appears
weaker. Water-2 is capable of adopting very good O–H.p-
acceptor hydrogen-bond geometry while maintaining a
second hydrogen bond with Thr-242 or Water-3 (Fig. S6
B). Furthermore, the >C3–H of the cyclopropane ring has
excellent geometry for donating a hydrogen bond to
Water-2 (Fig. S6 D).
The hydrogen bond between Tyr-236 and the ligands is
essential, because after the Tyr-236-Phe mutation, bound
CPM was not observed and inhibition of the kinase was
attenuated. The requirement for a hydrogen bond imposes
a geometric constraint that may account for the ligand
selectivity of this binding pocket. Thus, although ethanol
might form a hydrogen bond with Tyr-236, it is too short
to take part in van der Waals interactions with the backbone
of the phorbol-binding loop (e.g., Met-239). Butanol
and octanol are long enough for their third carbons to
make such interactions, but modeling suggests that this
would result in steric clashes with subsequent carbons.Biophysical Journal 103(11) 2331–2340
2338 Shanmugasundararaj et al.Furthermore, Tyr-236 is not hydrogen-bonded to water,
whereas other sites are (e.g., the Met-239 amide), so that
exchanging the water for an alcohol hydrogen bond is less
advantageous. This may account for the remarkable obser-
vation that 10 M ethanol in 55 M water cannot displace
Water-1. In fact, electron density attributable to ethanol is
not seen anywhere in the structure, suggesting that the struc-
tural requirements for tight ethanol binding are quite strict
and in no way nonspecific.Role of solvation
Water contributes to anesthetic binding in two ways, one
entropic and the other enthalpic. Removal of some of the
anesthetic’s hydrophobic surface from solvation by water
will be entropically favorable (the hydrophobic effect). In
addition, in the native state, the anesthetic binding pocket
is occupied by a water molecule hydrogen-bonded to the
backbone nitrogen of Met-239 (3.1 A˚) that is displaced
when the ligands bind (Fig. 3), thus compensating for the
entropic cost of confining a freely diffusing anesthetic mole-
cule to the binding pocket. An enthalpic contribution of
water comes from tight van der Waals interactions with the
twowater molecules that form one side of the binding pocket
between Thr-242 and Lys-260, and from the solvation of
the displaced water, which would be expected to compensate
for the loss of its single hydrogen bond with the protein.
When the previously published (31) phorbol-bound struc-
ture is superimposed on our higher-resolution structure,
a dramatic role for the solvent is revealed. Nine of the 11
waters in our structure are isosteric with the phorbol and
must be displaced by phorbol binding. One of these
(Water-28) is isosteric with phorbol oxygen O20, so that
upon binding, the phorbol O20 replaces the hydrogen
bond between Water-28 and the backbone nitrogen of Thr-
242. Notably, Water-28 has the lowest B-factor (20 A˚2,
compared to 26–49 A˚2 for the others). One of the remaining
waters (Water-155; Fig. S2 B, green) loses its hydrogen
bond to Water-146, which is displaced by phorbol binding,
and forms one with O3 of the phorbol ester.Site of kinase inhibition
When PKCd activity was stimulated by using PMA, which
binds exclusively to the C1B domain of PKCd adjacent to
the alcohol site we have characterized, 300 mM CPM in-
hibited activity by ~30%. However, introduction of the
Tyr-236-Phe mutation in C1B reduced the inhibition
dramatically, suggesting that the inhibitory site is located
on this domain in the same locus observed in the structure.
As a control, we examined CPM’s action on activity stimu-
lated by DG, which acts exclusively on the C1A domain,
finding that the wild-type and mutated kinases were equally
inhibited. These findings are consistent with CPM inhibiting
phorbol-induced kinase activity by binding to the site nearBiophysical Journal 103(11) 2331–2340Tyr-236 on the C1B domain of PKCd, whereas inhibition
of DG-induced activity must occur at another site. This
conclusion is consistent with the hypothesis of Stubbs and
co-workers that alcohols interact at or close to the phor-
bol-binding site of PKC (28).
PKCd is one of the isoforms least sensitive to anesthetic
action (30), so we were unable to pursue the mechanism
in more detail. PKCε is quite sensitive to ethanol and has
been photolabeled at His-236 (55), a residue homologous
to Tyr-236 in PKCd. Many of the residues in the putative
alcohol site in PKCε differ from those in the d-isoform,
perhaps accounting for the different sensitivities to alcohols.
This suggests that our findings may be relevant to other
isoforms of PKC, and structural information on these iso-
forms is eagerly awaited.
The mechanism by which anesthetic binding at the
Tyr-236 pocket of the kinase affects PMA-stimulated kinase
activity needs to be studied further. We have studied anes-
thetic interactions with a single conformation of the C1B
domain of PKCd, and that conformation is the same one
studied with and without phorbol ester bound (31). In both
studies, ligand-induced structural changes were modest,
even when the ligands were co-crystallized with the protein.
Zhang and Hurley (31) concluded ". that phorbol esters
activate PKC by altering the nature of the protein surface
and by stabilizing the membrane-inserted state, rather than
by inducing a conformational change at the activator-binding
site." On the other hand, a solution structure of the C1 domain
of Munc13-1 reveals a conformation change upon ligand
binding. A conserved tryptophan (Trp-252 in our structure)
occluded the binding cleft, which meant that a conforma-
tion change would be required before diacylglycerol could
bind (56). Thus, the possibility that anesthetics cause allo-
steric interactions in C1B domains cannot be dismissed.
There are no structures of intact novel PKCs, but the
structure of PKCb, a conventional PKC, has been solved
at 4.0 A˚ (57). The C1B domain clamps the NFD helix of
the kinase domain in its phorbol-binding cleft, a situation
that is reversed upon activation, indicating that this region
is involved in state transitions. In a similar way, the C1
domain of b2-chimaerin interacts with four other domains
that also occlude the phorbol-binding site (58). The back-
bone of the C1 domain in both these structures differs little
from that in PKCd C1B. In each case, the homologous anes-
thetic binding pocket faces the solvent, allowing unhindered
access for anesthetics, so that one cannot rule out allosteric
actions on interdomain interactions.CONCLUSIONS
We have characterized at very high resolution a binding
site for an ether and an alcohol in a surface pocket of the
PKCd C1B domain. Binding involves displacement of
a water molecule and the rearrangement of a single side
chain in the binding pocket. An unusual feature of the
Anesthetic Site on Protein Kinase Cd’s C1B Domain 2339binding pocket is that one side is bounded by two water
molecules held in place by a hydrogen-bonding chain
between two residues. These waters move modestly to
accommodate the ligand, providing the pocket with some
elasticity. Although van der Waals interactions contribute
to binding, a hydrogen bond between the ligand and
Tyr-236 is essential, because mutation of Tyr-236 to Phe
abolishes ligand binding. The requirement to maintain
both hydrogen bonding and van der Waals interactions
imposes geometric constraints that account for why ethanol
does not bind. It is possible that the cyclopropane ring plays
a unique role as a p-acceptor for X–H hydrogen bonds. The
binding site, whose structure we have characterized, medi-
ates inhibition of phorbol-induced PKCd activity by anes-
thetics, as shown by site-directed mutagenesis studies of
the kinase itself.Coordinates
The coordinates and structure factors have been deposited
in the Protein Data Bank (accession codes 3UEJ, 3UGL,
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